Skip links

Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ: Androgen receptor expression during the estrogen receptor-bad breast cancer

Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ: Androgen receptor expression during the estrogen receptor-bad breast cancer

Bieche We, Parfait B, Tozlu S, Lidereau R, Vidaud Meters: Quantitation out of androgen receptor gene expression within the sporadic nipple tumors by real-time RT-PCR: evidence you to definitely MYC was a keen AR-managed gene. Carcinogenesis. 2001, 22 (9): 1521-1526. /carcin/twenty-two.9.1521.

Bratthauer GL, Lininger RA, Child YG, Tavassoli FA: Androgen and you will estrogen receptor mRNA position for the apocrine carcinomas. Diagn Mol Pathol. 2002, 11 (2): 113-118. 9606-200206000-00008.

Gatalica Z: Immunohistochemical studies of apocrine breast sores. Uniform over-phrase regarding androgen receptor followed by the increasing loss of estrogen and you may progesterone receptors from inside the apocrine metaplasia and you may apocrine carcinoma into the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.

In the morning J Clin Pathol

Soreide JA, Lea OA, Varhaug JE, Skarstein A good, Kvinnsland S: Androgen receptors when you look at the operable breast cancer: reference to most other steroid hormonal receptors, correlations to prognostic affairs and you can predictive really worth to have effect of adjuvant tamoxifen cures. Eur J Surg Oncol. 1992, 18 (2): 112-118.

Bayer-Gather IB, Smoller B: Androgen receptors: good marker to boost awareness for identifying cancer of the breast into the facial skin metastasis off unknown pri, 13 (2): 119-122. /modpathol.3880021.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic pastime and you can scientific implications. J Clin Oncol. 2000, 18 (5): 1135-1149.

Pang ST, Flores-Morales A beneficial, Skoog L, Chuan YC, Nordstedt Grams, Pousette An excellent: Controls from matrix metalloproteinase thirteen phrase because of the androgen during the prostate cancers. Oncol Agent. 2004, 11 (6): 1187-1192.

Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.

Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Investigations of prognostic significance of androgen receptor expression within the metastatic breast cancer. Virchows Arch. 2006, 449 (1): 24-31. /s00428-006-0213-6.

Parker RL, Huntsman DG, Lesack DW, Cupples JB, Give DR, Akbari M, Gilks CB: Analysis of interlaboratory type on immunohistochemical dedication from the hormone estrogen receptor standing having fun with a breast cancer structure microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.

Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Examination of matrix metalloproteinases in addition to their inhibitors in the cancer of the breast. Br J Malignant tumors. 2007, 96 (6): 903-911. /sj.bjc.6603666.

Narita D, Raica Meters, Suciu C, Cimpean A beneficial, Anghel Good: Immunohistochemical term away from androgen receptor and you can prostate-certain antigen during the cancer of the breast. Folia Histochem Cytobiol. 2006, forty two (3): 165-172.

Egeblad Yards, Werb Z: New services with the matrix metalloproteinases during the disease progression. Nat Rev Cancer tumors. 2002, dos (3): 161-174. /nrc745.

Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–towards main stage out of cancer?. Cancer Cellphone. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.

Manes S, Llorente Meters, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Elizabeth, Martinez Air conditioning: The newest matrix metalloproteinase-9 controls brand new insulin-including development foundation-caused autocrine effect when you look at the DU-145 carcinoma structure. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..

Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel Age, Matrisian LM, Mareel M: Launch of an invasion supporter Age-cadherin fragment from the matrilysin and stromelysin-1. J Telephone Sci. 2001, 114 (Pt 1): 111-118.

Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] term selects to have cells with reduced susceptibility to help you apoptosis. Neoplasia. 2001, 3 (6): 459-468. /sj.neo.7900190.


Stetler-Stevenson WG: Matrix metalloproteinases from inside the angiogenesis: a relocation address to possess therapeutic input. J Clin Dedicate. 1999, 103 (9): 1237-1241. /JCI6870.

Cornelius Los angeles, Nehring LC, Harding Age, Bolanowski M, Welgus HG, Kobayashi DK, Penetrate RA, Shapiro SD: Matrix metalloproteinases generate angiostatin: consequences towards the neovascularization. J Immunol. 1998, 161 (12): 6845-6852.

Jiang Y, Goldberg ID, Shi YE: Complex opportunities regarding structure inhibitors out-of metalloproteinases from inside the cancers. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.

Return to top of page